Attendee search 

Founded in 1999, BGI is one of the world's leading life science and genomics organizations.

Healthcare VC

Big Pharma

华润集团一级利润中心，聚焦生命科学领域投资与合作

Genetron

WuXi Apptec provides a broad portfolio of R&D and manufacturing service that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients.

Haisco focus on the innovative drugs and the high-end drugs, and we seek collaborative partners for the previous drugs.

EpimAb's innovative FIT-Ig technology offers a game-changing approach to a broad variety of bi-specific antibodies. The technology provides access to stable bi-specifics by applying conventional molecular biology techniques. FIT-Ig molecules demonstrate properties similar to therapeutically active antibodies. They are actually manufactured like antibodies using standard processes at yields and purities similar to antibodies, e.g. EMB01, our first candidate was developed from cell line to IND submission date in 15 months, produced 3,5 g/l in a standard cell line and was easily purified with 70% recovery. Further candidates are manufactured with even higher yields.

EpimAb is developing a portfolio of bispecific antibodies for the treatment of different oncology indications. The first asset, EMB01, a first in class dual c-Met and EGFR inhibitor, is currently being investigated in a PhI/II study for treatment of solid tumors.

EMB02 (IND filing Q2/2020) and EMB04 are immune oncology biologics and EMB06 (IND filing Q4/2020) is a bispecific T-cell engager. In addition EMB08 (IND filing 2021) is a bispecific fusion protein.

EpimAb is committed to diversifying its portfolio of FIT-Igs in order to further validate the flexibility and robustness of the format and its platform. The broad applicability of this technology enables EpimAb to pursue two concurrent strategies for commercializing the technology:

•      Grant licenses to other pharmaceutical companies to combine two antibodies into a FIT-Ig themselves. Through this initiative EpimAb intends to catalyze the broad use of FIT-Igs for the benefit of scientists, the medical community and eventually patients; and

•      Create and develop proprietary FIT-Igs enabling EpimAb to grow and develop a discovery and development organization, generate FIT-Igs of great value to patients and medical experts and also improve its technological approach to bi-specific antibodies for the benefit of the scientific community.

Mabgen Biotech is a Hengrui Group company, focusing on the CMC part of biologics development.

We are a clinical stage biopharma company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders